Research programme: vitamin D3 derivatives - Astellas PharmaAlternative Names: 1,25-D3 antagonists - Astellas; DLAM derivatives - Astellas; Vitamin D3 derivatives - Astellas
Latest Information Update: 16 Jul 2016
At a glance
- Originator Astellas Pharma
- Mechanism of Action Vitamin D3 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- No development reported Bone disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bone-disorders in Japan
- 03 Jul 2006 Preclinical trials in Bone disorders in Japan (unspecified route)